Answers are grounded in this paper and cite their sources.
Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission. To date, 11 genome-wide significant susceptibility loci have been identified, mainly in European populations, leaving the genetic architecture in other ancestries incompletely characterized. We selected six MG genome-wide association study (GWAS) datasets, including four from European cohorts (International Myasthenia Gravis Genomics Consortium, Braun et al. (2024), UK Biobank and FinnGen) and two from East Asian cohorts (BioBank Japan and Taiwan Precision Medicine Initiative), with a maximum sample size of 1,852,227 (7,362 MG cases and 1,844,865 controls) and 4.03%-5.53% sample overlap. European-specific and cross-ancestry meta-analyses were performed using fixed-effect inverse-variance weighting (IVW) implemented in METAL, along with two additional sample overlap-adjusted methods, including the METAL OVERLAP option and N -weighted multivariate GWAMA. A series of post-GWAS analyses were further performed including functional annotation, conditional analysis, fine-mapping, gene mapping, transcriptome-wide and proteome-wide association studies, colocalization, summary-data-based Mendelian randomization, single-cell transcriptomics, and drug-gene interaction analyses. GWAS meta-analyses identified 23 independent genome-wide significant ( p < 500E-08) MG loci. Sample overlap-adjusted meta-analyses further confirmed 15 of the 23 loci with genome-wide significance, including seven potentially novel loci ZBED9 , GPR85 , PCM1 , SMTNL1 , THEMIS , UBASH3A , and KCTD1 . Integrative analyses prioritized 556 candidate genes, with 165 differentially expressed in immune cells. Multiomics analysis consistently highlighted CTSH as a high-confidence susceptibility gene. Gene-set analysis implicated immune-regulatory pathways, particularly T-cell activation, immune tolerance, and natural killer cell function, and tissue analysis showed enrichment of MG heritability in blood and lung. Genetic correlation and Mendelian randomization analyses identified significant genetic and/or causal relationships between MG and other autoimmune phenotypes, including rheumatoid arthritis and thyroid disorders. Drug-gene interaction analysis identified 109 potential therapeutic targets, especially CLEC16A- glatiramer acetate (interaction score = 15) and CFB- iptacopan (interaction score = 26.25). Our largest cross-ancestry GWAS to date substantially expands the MG genetic landscape. Our findings support dysregulated adaptive immunity as a central mechanism, prioritize biologically relevant risk genes and therapeutic targets, and provide a resource for future mechanistic and precision medicine studies.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: